Released Mar 13, 2018, after the close
10-K filed Mar 13, 2018, 72 days after period end · 0000926617-18-000012
Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$798.00K$798.00K derived−0.9% vs Q4 2016+14.2% vs Q3 2017
Net Income-$2.96M-$2.96M derivedN/M vs Q4 2016N/M vs Q3 2017
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$84,000+115.4%
Operating Incomederived-$2,940,000N/M
Operating Cash Flowderived-$2,152,000N/M
Free Cash Flowderived-$2,156,000N/M
Margins · derived
Gross margin10.5%+5.7 pt vs Q4 2016
Operating margin-368.4%−16.6 pt vs Q4 2016
Net margin-370.3%−16.8 pt vs Q4 2016
What the release said
The release
Same quarter
| Metric | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures |
|---|---|---|---|---|
| Revenue | $798.00K | $805.00K | $361.00K | $1.57M |
| Net Income | -$2.96M | -$2.85M | -$4.98M | -$4.08M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aspira Women's Health Inc. · CIK 926617 · Engraved from SEC EDGAR